Association of immune-related adverse events and outcomes in kidney cancer

Previous studies have shown that cancer patients who experience immune-related side effects (immune-related adverse events) when treated with immunotherapy may have a better response to treatment. This study looks at this effect in patients with metastatic renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (immunotherapy). In the study, 43 patients with metastatic RCC were […]

read more

Patients with autoimmune disorders have more immune-related side effects to immunotherapy

A study published in The Oncologist recently shows that patients with pre-existing autoimmune disorders are at an increased risk of developing immune-related side effects when treated with immunotherapy. This is regardless of tumour type, gender and general wellbeing. However, these patients can still be treated with immunotherapy. The study included 751 patients with four different […]

read more

Immunotherapy for the treatment of metastatic sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, such as sunitinib and pazopanib. This study […]

read more

Managing immune-related adverse events

In these video interviews, Dr Eric Jonasch from MD Anderson Cancer Center in Texas and Dr Monty Pal from the City of Hope Hospital in California talk about immune-related adverse events in people with advanced kidney cancer taking combination therapies and immunotherapy: Managing Adverse Events Among RCC Patients Receiving Combination Treatment With Targeted Therapy and […]

read more

Checkpoint inhibitor re-challenge after immune-related adverse events

Immunotherapy has revolutionised treatment in many cancers, including renal cell carcinoma (RCC). This study looked at giving patients immunotherapy after they had experienced an immune-related adverse event. With nivolumab in RCC, the probability of having a severe or life-threatening adverse event is very low. Nivolumab alone is very well tolerated. However, with the ipilimumab plus […]

read more

Survivorship and immune checkpoint inhibitors

In a study reported in the August issue of the European Journal of Cancer, a group of American investigators reported findings from patients with melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) who survived longer than two years after treatment with PD-1 and PD-L1 inhibitors (immune checkpoint inhibitors). In conclusion, most patients […]

read more

Long term follow-up of immune-related adverse events in cancer survivors

In this study carried out at a single hospital 217 cancer patients, who had at least 2 years follow-up data after treatment with immune checkpoint inhibitors (PD-1 or PD-L1), were followed-up long term for adverse events and health-related quality of life (HRQoL). There were 44 patients with renal cell carcinoma (RCC) in the study. Other […]

read more

Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab

In a paper published in Clinical Genitourinary Cancer the link between immune-related adverse events and clinical outcomes in patients with metastatic renal cell carcinoma (RCC) was investigated. One hundred and sixty seven (167) patients were included in the study. Of these, 46% had an immune-related adverse event, of which 8.9% were severe or life-threatening. However, […]

read more

Safety and efficacy of restarting immune checkpoint inhibitors after immune-related adverse events

Immune checkpoint inhibitors can cause a number of immune-related adverse events (irAEs) of various degrees of severity, such as colitis, pneumonitis, hypothyroidism, liver problems and skin rashes. A recent multi-centre, retrospective study published in Journal for Immunotherapy of Cancer investigated the safety and efficacy of re-treatment with immune checkpoint inhibitors, such as nivolumab and ipilimumab […]

read more

Assessing and managing adverse events to immunotherapies

In this video interview, Brenda Martone discusses the clinical nurse specialist’s role in assessing and managing immune-related complications and toxicities associated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. Brenda notes that immune-related reactions may occur months after a single dose of the immune checkpoint inhibitors. Immune-related reactions may include diarrhoea and colitis, […]

read more
Showing 1 to 10 of 15 results
  TOP